Heparin dosing in patients undergoing coronary intervention.

[1]  W. O’Neill,et al.  Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. , 1999, Journal of the American College of Cardiology.

[2]  P. Lyden,et al.  The diagnostic accuracy of bedside and laboratory coagulation: procedures used to monitor the anticoagulation status of patients treated with heparin. , 1998, American journal of clinical pathology.

[3]  Marc Cohen,et al.  One Year Follow-up of the ESSENCE Trial (enoxaparin Versus Heparin in Unstable Angina and Non-Q-Wave Myocardial Infarction) , 1998 .

[4]  T. Liem,et al.  Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndrome. , 1998, Journal of vascular surgery.

[5]  J. Bronzwaer,et al.  High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. , 1998, Journal of the American College of Cardiology.

[6]  G. Pesola,et al.  Heparin dosing for percutaneous coronary angioplasty: Use of body surface area to improve initial activated clotting time values , 1997, Clinical cardiology.

[7]  J. Zidar.  Rationale for low-molecular weight heparin in coronary stenting. , 1997, American heart journal.

[8]  T. Investigators.  Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. , 1997, Circulation.

[9]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[10]  J. Tijssen,et al.  Safety of low dose heparin in elective coronary angioplasty. , 1997, Heart.

[11]  Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.  Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II , 1997, The Lancet.

[12]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[13]  H. Benamer,et al.  A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty. , 1997, European heart journal.

[14]  R. Califf,et al.  Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. , 1997, The American journal of cardiology.

[15]  K. Fan,et al.  Use of low molecular weight heparin in postangioplasty management. , 1997, International journal of cardiology.

[16]  R. Califf,et al.  Relation between activated clotting time during angioplasty and abrupt closure. , 1996, Circulation.

[17]  C. Visser,et al.  Value of magnetic resonance imaging in assessing patency and function of coronary artery bypass grafts. An angiographically controlled study. , 1996, Circulation.

[18]  R. Califf,et al.  Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: Results from the IMPACT-II trial , 1996 .

[19]  W. Walsh,et al.  Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty. , 1996, Catheterization and cardiovascular diagnosis.

[20]  B. Chaitman,et al.  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.

[21]  P. Serruys,et al.  A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. , 1995, The New England journal of medicine.

[22]  M. Savage,et al.  Acute myocardial infarction during coronary angioplasty associated with heparin-induced thrombocytopenia. , 1995, Catheterization and cardiovascular diagnosis.

[23]  W. O’Neill,et al.  Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. , 1994, Journal of the American College of Cardiology.

[24]  J. Ferguson,et al.  The use of activated clotting times to monitor heparin therapy during and after interventional procedures , 1994, Clinical cardiology.

[25]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[26]  C. Gaos,et al.  Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. , 1994, Journal of the American College of Cardiology.

[27]  P. Fail,et al.  Subcutaneous heparin in postangioplasty management: comparative trial with intravenous heparin. , 1993, American heart journal.

[28]  E. Topol,et al.  Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time. , 1993, The Canadian journal of cardiology.

[29]  M. Leon,et al.  Vascular Complications After Balloon and New Device Angioplasty , 1993, Circulation.

[30]  W. Laskey,et al.  Prolonged heparin therapy for occlusive intracoronary thrombus. , 1993, Catheterization and cardiovascular diagnosis.

[31]  C. Simpfendorfer,et al.  Is aggressive heparinization necessary for elective PTCA? , 1993, Catheterization and cardiovascular diagnosis.

[32]  A. Gershlick,et al.  The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times. , 1993, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[33]  C. Gaos,et al.  Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. , 1992, Catheterization and cardiovascular diagnosis.

[34]  H. Hecht,et al.  Lesion morphology and coronary angioplasty: current experience and analysis. , 1992, Journal of the American College of Cardiology.

[35]  E. Topol,et al.  Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. , 1992, Journal of the American College of Cardiology.

[36]  P. Grayburn,et al.  In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: evidence for inadequate heparinization. , 1991, Catheterization and cardiovascular diagnosis.

[37]  P. Serruys,et al.  Acute Coronary Artery Occlusion During and After Percutaneous Transluminal Coronary Angioplasty: Frequency, Prediction, Clinical Course, Management, and Follow‐up , 1991, Circulation.

[38]  D. Faxon,et al.  Incidence and consequences of periprocedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. , 1990, Circulation.

[39]  W. Laskey,et al.  Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in unstable angina pectoris. , 1990, The American journal of cardiology.

[40]  W. Laskey,et al.  Influence of heparin therapy on percutaneous transluminal coronary angioplasty outcome in patients with coronary arterial thrombus. , 1990, The American journal of cardiology.

[41]  M. L. Miller,et al.  Heparin-induced thrombocytopenia. , 1989, Cleveland Clinic journal of medicine.

[42]  S. Ellis,et al.  Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. , 1989, American heart journal.

[43]  L Schwartz,et al.  Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. , 1988, The New England journal of medicine.

[44]  J. Haft,et al.  Heparin resistance induced by intravenous nitroglycerin. A word of caution when both drugs are used concomitantly. , 1987, Archives of internal medicine.

[45]  T. Ryan,et al.  Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. , 1987, Circulation.

[46]  V. Fuster,et al.  Influence of Arterial Damage and Wall Shear Rate on Platelet Deposition: Ex Vivo Study in a Swine Model , 1986, Arteriosclerosis.

[47]  E. Anderson,et al.  Heparin resistance prior to cardiopulmonary bypass. , 1986, Anesthesiology.

[48]  C. Kisker,et al.  Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. , 1978, The Annals of thoracic surgery.

[49]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. , 1975, The Journal of thoracic and cardiovascular surgery.

[50]  M. Kotler,et al.  Incidence of bleeding complications associated with abciximab huse in conjunction with thrombolytic therapy in patients requiring angioplasty , 1998 .

[51]  J. J. Ferguson.  All ACTs are not created equal. , 1992, Texas Heart Institute journal.

[52]  J. Hirsh.  Drug therapy : heparin , 1991 .